LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) and SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations and institutional ownership.
Insider and Institutional Ownership
54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by company insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of recent recommendations for LENZ Therapeutics and SELLAS Life Sciences Group, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| LENZ Therapeutics | 1 | 2 | 5 | 0 | 2.50 |
| SELLAS Life Sciences Group | 1 | 0 | 1 | 0 | 2.00 |
Profitability
This table compares LENZ Therapeutics and SELLAS Life Sciences Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| LENZ Therapeutics | -519.30% | -46.82% | -43.32% |
| SELLAS Life Sciences Group | N/A | -47.12% | -42.63% |
Risk and Volatility
LENZ Therapeutics has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, SELLAS Life Sciences Group has a beta of 2.5, indicating that its stock price is 150% more volatile than the S&P 500.
Earnings & Valuation
This table compares LENZ Therapeutics and SELLAS Life Sciences Group”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| LENZ Therapeutics | $20.99 million | 10.11 | -$82.13 million | ($3.60) | -1.88 |
| SELLAS Life Sciences Group | N/A | N/A | -$26.86 million | ($0.23) | -34.04 |
SELLAS Life Sciences Group has lower revenue, but higher earnings than LENZ Therapeutics. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
LENZ Therapeutics beats SELLAS Life Sciences Group on 8 of the 13 factors compared between the two stocks.
About LENZ Therapeutics
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
About SELLAS Life Sciences Group
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Receive News & Ratings for LENZ Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENZ Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
